Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, Lincoln's Inn Fields Laboratories, London WC2A 3LY, United Kingdom.
CRUK Lung Cancer Centre of Excellence/UCL Cancer Institute, London WC1E 6BT, United Kingdom.
Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):a028373. doi: 10.1101/cshperspect.a028373.
Chromosomal aberrations during cell division represent one of the first recognized features of human cancer cells, and modern detection methods have revealed the pervasiveness of aneuploidy in cancer. The ongoing karyotypic changes brought about by chromosomal instability (CIN) contribute to tumor heterogeneity, drug resistance, and treatment failure. Whole-chromosome and segmental aneuploidies resulting from CIN have been proposed to allow "macroevolutionary" leaps that may contribute to profound phenotypic change. In this review, we will outline evidence indicating that aneuploidy and CIN contribute to cancer evolution.
染色体畸变在细胞分裂过程中代表了人类癌细胞的最早特征之一，现代检测方法已经揭示了非整倍体在癌症中的普遍性。染色体不稳定性 (CIN) 引起的持续的核型变化导致肿瘤异质性、耐药性和治疗失败。CIN 导致的全染色体和片段性非整倍体被认为可以允许“宏观进化”的飞跃，从而可能导致显著的表型变化。在这篇综述中，我们将概述表明非整倍体和 CIN 有助于癌症进化的证据。
